Jeremy Bender

Jeremy Bender is the current CEO of Day One Biopharmaceuticals. Prior to this, they served as Vice President of Corporate Development at Gilead Sciences, Chief Business Officer at Sutro Biopharma, Inc., and Chief Operating Officer at Tizona Therapeutics. Jeremy has also served on the board of directors for SutroVax, Inc. and as Vice President of Corporate Development for Allos Therapeutics. Before their work in the biotech industry, Jeremy worked as a consultant for Boston Consulting Group.

Jeremy Bender received their MBA from the MIT Sloan School of Management, their Ph.D. in Microbiology and Immunology from the University of Colorado Anschutz Medical Campus, and their B.S. in Biology from Stanford University.

Eleni Venetsanakos - Sr. Director of Translational Sciences, Mike Preigh - Chief of Technology Operations, and Samuel Blackman - Co-founder and Chief Medical Officer report to Jeremy Bender.